Westfield Capital Management CO LP Neurocrine Biosciences Inc Transaction History

Westfield Capital Management CO LP

$21.2 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $2.41 Million - $2.64 Million	-18,416 Reduced 3.66%	484,777 $66.7 Million
Q1 2024 May 10, 2024	SELL	$130.4 - $143.74 $11.9 Million - $13.1 Million	-91,244 Reduced 15.35%	503,193 $69.4 Million
Q4 2023 Feb 09, 2024	SELL	$106.07 - $132.76 $5.82 Million - $7.28 Million	-54,855 Reduced 8.45%	594,437 $78.3 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $25.8 Million - $32.1 Million	273,952 Added 72.99%	649,292 $73 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $10.8 Million - $12.7 Million	120,714 Added 47.41%	375,340 $35.4 Million
Q1 2023 May 12, 2023	SELL	$94.11 - $123.02 $1.7 Million - $2.22 Million	-18,062 Reduced 6.62%	254,626 $25.8 Million
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $20 Million - $23.8 Million	-187,495 Reduced 40.74%	272,688 $32.6 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $6.32 Million - $7.4 Million	-68,662 Reduced 12.98%	460,183 $48.9 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $1.94 Million - $2.57 Million	-25,646 Reduced 4.63%	528,845 $51.6 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $11 Million - $14.4 Million	-151,735 Reduced 21.49%	554,491 $52 Million
Q4 2021 Feb 10, 2022	SELL	$79.65 - $106.22 $1.35 Million - $1.8 Million	-16,952 Reduced 2.34%	706,226 $60.1 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $9.32 Million - $10.7 Million	108,185 Added 17.59%	723,178 $69.4 Million
Q2 2021 Aug 10, 2021	BUY	$89.43 - $102.27 $7.04 Million - $8.05 Million	78,743 Added 14.68%	614,993 $59.9 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $6.32 Million - $8.62 Million	72,164 Added 15.55%	536,250 $52.2 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $5.2 Million - $6.48 Million	59,835 Added 14.8%	464,086 $44.5 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $460,125 - $646,692	4,785 Added 1.2%	404,251 $38.9 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $21.2 Million - $32.4 Million	-248,691 Reduced 38.37%	399,466 $48.7 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $48.7 Million - $73.7 Million	648,157 New	648,157 $56.1 Million
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $22.9 Million - $28.9 Million	-316,540 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $12 Million - $15.8 Million	172,800 Added 120.22%	316,540 $27.9 Million
Q4 2018 Feb 08, 2019	BUY	$68.32 - $124.36 $9.82 Million - $17.9 Million	143,740 New	143,740 $10.3 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $18.3 Million - $23.2 Million	-184,741 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$75.3 - $105.99 $13.9 Million - $19.6 Million	184,741 New	184,741 $18.1 Million
Q4 2017 Feb 13, 2018	SELL	$58.53 - $77.59 $22.4 Million - $29.7 Million	-383,097 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $18.4 Million - $23.5 Million	383,097	383,097 $23.5 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

93.9M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$2.08 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.47 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$756 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$378 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$274 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

News

Stay updated on Westfield Capital Management CO LP with notifications on news.

Account